Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
NVCR Novocure
94.220
-0.870-0.91%
Post Mkt Price
94.2200.0000.00%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
-1.95% 131M 5.50% 140.87M 2.12% 137.55M 8.23% 535.03M
Operating revenue
-1.95% 131M 5.50% 140.87M 2.12% 137.55M 8.23% 535.03M
Cost of revenue
-1.51% 29.75M -0.34% 28.5M 5.09% 27.73M 7.86% 114.88M
Gross profit
-2.08% 101.25M 7.10% 112.36M 1.39% 109.82M 8.32% 420.15M
Operating expense
12.42% 125.86M 13.89% 133.49M 2.06% 110.63M 29.94% 464.49M
Selling and administrative expenses
15.82% 73.9M 14.23% 76.42M 9.46% 68.39M 16.74% 263.18M
-Selling and marketing expense
27.06% 41.4M 31.09% 44.75M 20.82% 37.88M 16.13% 137.06M
-General and administrative expense
4.09% 32.51M -3.34% 31.67M -1.98% 30.51M 17.40% 126.13M
Research and development costs
7.92% 51.96M 13.44% 57.08M -8.02% 42.23M 52.49% 201.3M
Operating profit
-187.78% -24.61M -71.84% -21.13M -815.91% -806K -245.83% -44.33M
Net non-operating interest income expense
160.27% 1.19M -137.02% -2.23M 35.41% -1.71M 75.18% -3.71M
Non-operating interest income
-- -- -- -- -- -- -55.74% 791K
Non-operating interest expense
-- -- -- -- -- -- -73.83% 3.44M
Total other finance cost
-160.27% -1.19M 137.02% 2.23M -35.41% 1.71M -70.42% 1.06M
Other net income (expense)
-252.27% -4.03M
Gain on sale of security
-- -- -- -- -- -- -252.27% -4.03M
Income before tax
-122.32% -23.42M -76.47% -23.36M 8.01% -2.52M -387.68% -52.08M
Income tax
21.92% 3.16M -53.63% 652K 52.94% 2.13M 467.88% 6.28M
Net income
-102.50% -26.58M -63.98% -24.01M -12.57% -4.65M -394.58% -58.35M
Net income continuous Operations
-102.50% -26.58M -63.98% -24.01M -12.57% -4.65M -394.58% -58.35M
Minority interest income
Net income attributable to the parent company
-102.50% -26.58M -63.98% -24.01M -12.57% -4.65M -394.58% -58.35M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-102.50% -26.58M -63.98% -24.01M -12.57% -4.65M -394.58% -58.35M
Basic earnings per share
-92.31% -0.25 -64.29% -0.23 0.00% -0.04 -380.00% -0.56
Diluted earnings per share
-92.31% -0.25 -64.29% -0.23 0.00% -0.04 -411.11% -0.56
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
CEO: Mr. Asaf Danziger
Market: NASDAQ
Listing Date: 10/02/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist